The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Disc Medicine Inc shares valued at $104,519 were sold by Franchi Jean M. on Jun 16 ’25. At $52.26 per share, Franchi Jean M. sold 2,000 shares. The insider’s holdings dropped to 67,530 shares worth approximately $3.38 million following the completion of this transaction.
Also, JEAN FRANCHI purchased 2,000 shares, netting a total of over 107,420 in proceeds.
Before that, Savage William Jacob had sold 2,996 shares from its account. In a trade valued at $149,800, the Chief Medical Officer traded Disc Medicine Inc shares for $50.00 each. Upon closing the transaction, the insider’s holdings decreased to 2,996 shares, worth approximately $2.84 million.
Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in late February. As of November 05, 2024, Morgan Stanley has increased its “an Equal-weight” rating to a “an Overweight” for IRON. Earlier on November 04, 2024, Raymond James upgraded its rating. Their new recommendation was “a Strong buy” for IRON stock which previously was a “an Outperform”.
Analyzing IRON Stock Performance
On last trading session,, Disc Medicine Inc [NASDAQ: IRON] rose 0.08% to $50.09. During the last five days, there has been a drop of approximately -1.51%. Over the course of the year, Disc Medicine Inc shares have dropped approximately -20.99%. Shares of the company reached a 52-week high of $65.02 on 01/02/25 and a 52-week low of $30.82 on 04/09/25.
Support And Resistance Levels for Disc Medicine Inc (IRON)
According to the 24-hour chart, there is a support level at 48.92, which, if violated, would cause prices to drop to 47.76. In the upper region, resistance lies at 51.20. The next price resistance is at 52.31. RSI (Relative Strength Index) is 52.89 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Disc Medicine Inc (IRON)?
In terms of Disc Medicine Inc share price expectations, FactSet research, analysts set an average price target of 70.5 in the next 12 months, up nearly 40.86% from the previous closing price of $50.05. Analysts anticipate Disc Medicine Inc stock to reach 112 by 2025, with the lowest price target being 43. In spite of this, 9 analysts ranked Disc Medicine Inc stock as Buy at the end of 2025. On October 23, 2024, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $89.
